Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RUNX1 mutation
i
Other names:
RUNX1, RUNX Family Transcription Factor 1, Runt-Related Transcription Factor 1, Polyomavirus Enhancer-Binding Protein 2 Alpha B Subunit, SL3/AKV Core-Binding Factor Alpha B Subunit, SL3-3 Enhancer Factor 1 Alpha B Subunit, Runt Related Transcription Factor 1, Acute Myeloid Leukemia 1 Protein, Oncogene AML-1, PEBP2-Alpha B, PEA2-Alpha B, AMLCR1, CBFA2, AML1, Core-Binding Factor Subunit Alpha-2, AML1-EVI-1 Fusion Protein, Acute Myeloid Leukemia 1, Aml1 Oncogene, CBF-Alpha-2, AML1-EVI-1, PEBP2alpha
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
861
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
RUNX1 mutation
Myelodysplastic Syndrome
RUNX1 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
RUNX1 mutation
Chronic Myelomonocytic Leukemia
RUNX1 mutation
Chronic Myelomonocytic Leukemia
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
RUNX1 mutation
Myelodysplastic Syndrome
RUNX1 mutation
Myelodysplastic Syndrome
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
RUNX1 mutation
Myelodysplastic Syndrome
RUNX1 mutation
Myelodysplastic Syndrome
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
venetoclax + RG7388
Sensitive: C3 – Early Trials
venetoclax + RG7388
Sensitive
:
C3
venetoclax + RG7388
Sensitive: C3 – Early Trials
venetoclax + RG7388
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
LY3009120
Resistant: C3 – Early Trials
LY3009120
Resistant
:
C3
LY3009120
Resistant: C3 – Early Trials
LY3009120
Resistant
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Resistant: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Resistant
:
C3
cytarabine/daunorubicin liposomal formulation
Resistant: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Resistant
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
cytarabine
Resistant: C3 – Early Trials
cytarabine
Resistant
:
C3
cytarabine
Resistant: C3 – Early Trials
cytarabine
Resistant
:
C3
RUNX1 mutation
Myelodysplastic Syndrome
RUNX1 mutation
Myelodysplastic Syndrome
azacitidine
Resistant: C3 – Early Trials
azacitidine
Resistant
:
C3
azacitidine
Resistant: C3 – Early Trials
azacitidine
Resistant
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
cytarabine + clofarabine
Sensitive: C3 – Early Trials
cytarabine + clofarabine
Sensitive
:
C3
cytarabine + clofarabine
Sensitive: C3 – Early Trials
cytarabine + clofarabine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
cytarabine + cladribine
Sensitive: C3 – Early Trials
cytarabine + cladribine
Sensitive
:
C3
cytarabine + cladribine
Sensitive: C3 – Early Trials
cytarabine + cladribine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
RUNX1 mutation
Chronic Myeloid Leukemia
RUNX1 mutation
Chronic Myeloid Leukemia
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
Tyrosine kinase inhibitor
Resistant
:
C3
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
Tyrosine kinase inhibitor
Resistant
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
BTX-A51
Sensitive: C3 – Early Trials
BTX-A51
Sensitive
:
C3
BTX-A51
Sensitive: C3 – Early Trials
BTX-A51
Sensitive
:
C3
RUNX1 mutation
Myelodysplastic Syndrome
RUNX1 mutation
Myelodysplastic Syndrome
sintilimab
Sensitive: C3 – Early Trials
sintilimab
Sensitive
:
C3
sintilimab
Sensitive: C3 – Early Trials
sintilimab
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
venetoclax + decitabine/cedazuridine
Sensitive: C3 – Early Trials
venetoclax + decitabine / cedazuridine
Sensitive
:
C3
venetoclax + decitabine/cedazuridine
Sensitive: C3 – Early Trials
venetoclax + decitabine / cedazuridine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
tagraxofusp-erzs
Sensitive: D – Preclinical
tagraxofusp-erzs
Sensitive
:
D
tagraxofusp-erzs
Sensitive: D – Preclinical
tagraxofusp-erzs
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login